U.S. markets closed

Aldeyra Therapeutics, Inc. (ALDX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.2500-0.1500 (-3.41%)
At close: 04:00PM EDT
4.1600 -0.09 (-2.12%)
After hours: 05:48PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close4.4000
Bid4.2100 x 100
Ask4.3000 x 200
Day's Range4.1900 - 4.4700
52 Week Range1.4200 - 11.9700
Avg. Volume588,674
Market Cap250.307M
Beta (5Y Monthly)1.52
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ALDX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Aldeyra Therapeutics, Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • Zacks

    Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why

    Aldeyra (ALDX) rises 43% in one week, driven by plans to initiate a pivotal study to support the resubmission of reproxalap NDA for dry eye disease in the first half of 2024.

  • Zacks

    Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

    Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.

  • The Wall Street Journal

    Health Care Roundup: Market Talk

    0957 ET – Overhang on GSK shares from litigation surrounding the heartburn drug Zantac is likely to diminish after peer Sanofi agreed in principle to settle thousands of claims in the U.S., Barclays analysts say in a note. Sanofi’s agreement to settle claims around allegations that Zantac caused cancer is positive, indicating GSK will also seek settlements, they say. “We believe that we’re highly unlikely to see any Zantac case go to trial with either GSK or Sanofi as a named defendant,” the analysts add.